Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administration of Dose A of ACI-24.060 in Study Part 2. Dose A will be a dose already tested in Study Part 1a”In the company’s words, NCT05462106 on ClinicalTrials.gov
- Tested for
- Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
- Main trialPhase 1/2
- “The purpose of this study is to assess the safety, tolerability, immunogenicity and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndrome.”In the company’s words, NCT05462106 on ClinicalTrials.gov
Other drugs for Prodromal Alzheimer's Disease
- LecanemabEisai · Biogen · Phase 3
- Verenafusp alfaAO GENERIUM · Phase 2/3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
- FlorbetazineHTA Co., Ltd. · Phase 3
- TrontinemabRoche · Phase 3
- DonanemabEli Lilly · Phase 3
Coming up1
- Apr 2029Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Apr 2029 | A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026